Active Pharmaceutical Ingredients - Dr Reddy's
Active Pharmaceutical Ingredients - Dr Reddy's

About Acalabrutinib API

Product
  • Categoría Terapéutica Anti-Cáncer / Oncologico

  • Número CAS

    870524-78-5

  • Tecnología del API

    Molécula pequeña

  • Forma de Dosificación

    Sólido Oral/Cápsulas

  • Estado de Desarrollo en Dr. Reddy’s

    En desarrollo

Mechanism of Action

Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor. BTK is a protein that plays an important role in the survival and growth of B cells. By blocking BTK, acalabrutinib can help to slow down or even stop the growth of cancer cells.

Indication

The FDA approved Acalabrutinib for the treatment of adult patients with Mantle Cell Lymphoma (MCL) has received at least one prior therapy. Chronic lymphocytic leukemia (CLL). Small lymphocytic lymphoma (SLL).

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Select Product *
Select Regulatory Requirements
Select Purpose

Related APIs

Acetato De Abiraterona

Anti-Cáncer / Oncologico

arrow

Nilotinib Clorhidrato

Anti-Cáncer / Oncologico

arrow

Lomustina

Anti-Cáncer / Oncologico

arrow

Azacitidina

Anti-Cáncer / Oncologico

arrow

Clorhidrato De Bendamustina

Anti-Cáncer / Oncologico

arrow

Bortezomib

Anti-Cáncer / Oncologico

arrow

Cabazitaxel

Anti-Cáncer / Oncologico

arrow

Cabozantinib S-Malate

Anti-Cáncer / Oncologico

arrow

Capecitabina

Anti-Cáncer / Oncologico

arrow

Carfilzomib

Anti-Cáncer / Oncologico

arrow

Decitabina

Anti-Cáncer / Oncologico

arrow

Deucravacitinib

Anti-Cáncer / Oncologico

arrow

Gemcitabine Hydrochloride

Anti-Cáncer / Oncologico

arrow

Pazopanib

Anti-Cáncer / Oncologico

arrow

Pomalidomida

Anti-Cáncer / Oncologico

arrow

Relugolix

Anti-Cáncer / Oncologico

arrow

Ripretinib

Anti-Cáncer / Oncologico

arrow

Darolutamide

Anti-Cáncer / Oncologico

arrow

Fruquintinib

Anti-Cáncer / Oncologico

arrow

Zanubrutinib

Anti-Cáncer / Oncologico

arrow

Ácido Zoledrónico

Anti-Cáncer / Oncologico

arrow

Venetoclax

Anti-Cáncer / Oncologico

arrow

Tucatinib

Anti-Cáncer / Oncologico

arrow

Cabozantinib HCl

Anti-Cáncer / Oncologico

arrow

Dasatinib

Anti-Cáncer / Oncologico

arrow

Enzalutamida

Anti-Cáncer / Oncologico

arrow

Mesilato De Eribulina

Anti-Cáncer / Oncologico

arrow

Lenalidomida

Anti-Cáncer / Oncologico

arrow

Pemetrexed Disodium (Heptahidrato)

Anti-Cáncer / Oncologico

arrow

Granisteron

Anti-Cáncer / Oncologico

arrow

Midostaurina

Anti-Cáncer / Oncologico

arrow

Apalutamide (Amorphous & Form B)

Anti-Cáncer / Oncologico

arrow

Lenvatinib Mesylate (MIBK Solvate)

Anti-Cáncer / Oncologico

arrow

Lenvatinib Mesylate (Form-C)

Anti-Cáncer / Oncologico

arrow

Adagrasib

Anti-Cáncer / Oncologico

arrow

Pirtobrutinib

Anti-Cáncer / Oncologico

arrow

Palbociclib

Anti-Cáncer / Oncologico

arrow

Descargo de responsabilidad

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.